Synuclein

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on: 
Monday, March 11, 2024
Aggregation, Enzyme, Pathology, Neuron, Treatment, Skill, Synuclein, ELISA, Neurodegenerative disease, Conference, Antibody, IHC, Therapy, Death, Patient, Synucleinopathy, Three-body problem, DSF, SPR, Brain

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points: 
  • The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
  • A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
  • It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
  • Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of  prasinezumab, which targets non-nitrated α-synuclein.

AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease

Retrieved on: 
Tuesday, September 12, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Alpha-synuclein, PD, Centrifugation, Celsius, Neurodegenerative disease, The Michael J. Fox Foundation, Tears, II, Organization, Bicinchoninic acid assay, Parkinson's disease, Synuclein, Patient, Freezing, Lactoferrin, Diagnosis, III, Alzheimer's disease, Medical imaging, Palladium

Fox Foundation shows that the presence of abnormal alpha-synuclein was detected in an astonishing 93% of people with Parkinson’s who participated in the study.

Key Points: 
  • Fox Foundation shows that the presence of abnormal alpha-synuclein was detected in an astonishing 93% of people with Parkinson’s who participated in the study.
  • These findings suggest a crucial role for α-synuclein in therapeutic development, both in identifying pathologically defined subgroups of people with Parkinson's disease and establishing biomarker-defined at-risk cohorts.
  • Total tear protein content is first quantified using a bicinchoninic acid assay followed by alpha-Synuclein using a bulky plate reader.
  • AXIM is already marketing a lactoferrin assay, which may be used in conjunction with the newly developed novel Synuclein test.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

Nitrase Therapeutics Presented New Findings on the Role of Synuclein Nitrase in Alpha Synuclein Nitration and Aggregation, as well as Motor Dysfunction at the 2023 Alzheimer's & Parkinson's Diseases (AD/PD) Conference

Retrieved on: 
Tuesday, March 28, 2023
Methamphetamine, Enzyme, Pathology, DSM-IV codes, Paralysis, Skill, Aggregation, Synuclein, Poster, PFF, Therapy, Conference, Pharmaceutical industry, Neuron

For the in vitro and in vivo preclinical studies; methamphetamine, preformed fibrils (PFF) spread and Synuclein transgenic models were used, whereby Synuclein Nitrase activity was reduced using either a small molecule pan-Nitrase inhibitor (NB001) or Synuclein Nitrase knockout to investigate the role Synuclein Nitrase plays in αSyn nitration, αSyn aggregation, and paralysis. The results demonstrated that Synuclein Nitrase knockout prevents synuclein nitration in vitro and in vivo, and there was a decrease in nitration of αSyn in wild type mice who received NB001. Additionally, removal of Synuclein Nitrase reduced the formation of phospho-αSyn aggregates in both in vitro and in vivo models. Importantly, the Synuclein Nitrase knockout mice showed reduced in paralysis in a mouse model of Parkinson’s disease. Synuclein Nitrase impacts three key hallmarks of Parkinson’s disease -- αSyn nitration, αSyn aggregation, and motor dysfunction.

Key Points: 
  • The presentation titled, “Alpha Synuclein Nitration and Aggregation in Neurons is Controlled by the Novel Enzyme Synuclein Nitrase” (abstract #412; poster board #OD181) reviewed preclinical in vitro and in vivo data on the critical role of a Nitrase-discovered enzyme, Synuclein Nitrase, on alpha synuclein (αSyn) nitration, synuclein aggregation, and motor dysfunction in Parkinson’s disease.
  • “We have discovered a novel enzyme called Synuclein Nitrase, and these data suggest that alpha synuclein nitration and aggregation in neurons is controlled by this novel enzyme.
  • Additionally, removal of Synuclein Nitrase reduced the formation of phospho-αSyn aggregates in both in vitro and in vivo models.
  • Synuclein Nitrase impacts three key hallmarks of Parkinson’s disease -- αSyn nitration, αSyn aggregation, and motor dysfunction.

Amprion Exhibits at MDS International Congress of Parkinson's Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022

Retrieved on: 
Thursday, September 15, 2022
CSF, Rapid eye movement sleep behavior disorder, MD, Parkinson's disease, Prevalence, Research, International Congress on Tuberculosis, FDA, Alzheimer's disease, Neurodegeneration, PEKK, The Michael J. Fox Foundation, Company, Population, MDS, Person, Patient, Movement disorders, Neurological disorder, SAA, Physician, Synuclein, Diagnosis, Multiple system atrophy, Body, RBD, SAN, Disease, Ageing, Conference, PD, Cerebrospinal fluid, Disease management, Medical device, Medical imaging, Pharmaceutical industry, Amprion

SAN FRANCISCO, Sept. 15, 2022 /PRNewswire-PRWeb/ -- Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212. We look forward to discussing how the SYNTap® Biomarker Test addresses the unmet medical need for a validated clinical test to diagnose Parkinson's disease (PD) and differentiate PD from atypical Parkinson's at early stages. Accurate and early diagnosis helps accelerate personalized treatment and therapeutic innovations.

Key Points: 
  • Amprion will host a Meet the Expert session with Neurologist Brit Mollenhauer, MD, in which attendees can discuss scientific insights on how the SYNTap Test performs in a clinical setting.
  • In addition to the exhibit at MDS, Amprion Chief Scientific Officer Claudio Soto, Ph.D., will speak at International Conference Prion2022, September 13-16 in Gttingen, Germany.
  • SAN FRANCISCO, Sept. 15, 2022 /PRNewswire-PRWeb/ -- Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212.
  • Dr. Lebovitz will attend MDS, International Congress of Parkinson's Disease and Movement Disorders in Madrid, September 15-18.

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting

Retrieved on: 
Tuesday, April 12, 2022
Protein, GBA1, CBE, Alpha-synuclein, Glycogen storage disease, Lists of diseases, Synuclein, Pathology, Research, Gaucher's disease, The Michael J. Fox Foundation, Neuron, Drug discovery, GLOBE, Program, Patient, Lysosome, GBA, Nasdaq, AD, Neurodegeneration, General manager, Forward-looking statement, PD, MJFF, Therapy, Association, Pharmaceutical industry, Aroma compound, WT, Gaucher

The results were highlighted in a poster presentation at the 2022 Synuclein Meeting being held April 12 - 15, 2022, in Leuven, Belgium.

Key Points: 
  • The results were highlighted in a poster presentation at the 2022 Synuclein Meeting being held April 12 - 15, 2022, in Leuven, Belgium.
  • Eric Richman, Chief Executive Officer of Gain comments, The data we presented at the Synuclein Meeting demonstrates further encouraging disease modifying potential for patients with Parkinsons disease who currently have no effective treatment options.
  • The data was generated in two different in vitro models covering both WT and the two most pathogenic GBA1 mutations L444P and N370S.
  • Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx.

SYNTap Biomarker Test helps doctors distinguish Parkinson's Disease from Parkinsonism in early stages

Retrieved on: 
Wednesday, April 6, 2022
Linda, Substantia nigra, Chittagong Veterinary and Animal Sciences University, Southern Illinois University School of Medicine, Neurology, Diagnosis, Neurodegeneration, Oregon Health & Science University, Movement disorders, Dopamine, Body, Synuclein, School, Oregon Health Plan, PD, Basal ganglia, History, Alzheimer's disease, Neurological disorder, Progressive supranuclear palsy, Autopsy, Parkinson's disease, Time, Physician, Amprion, Movement, SAN, FDA, Patient, Disease, Medical imaging, Palladium, Pharmaceutical industry, Medical device, Parkinsonism

SAN FRANCISCO, April 6, 2022 /PRNewswire-PRWeb/ -- PD affects 10 million people globally. About one million Americans live with PD, and 60,000 new cases are added each year. Unfortunately, despite billions of spending in drug R&D over the past three decades, there is no cure for Parkinson's–yet.

Key Points: 
  • For the first time in history, Amprion's breakthrough SYNTap Biomarker Test can help doctors effectively distinguish Parkinson's Disease (PD) from Parkinsonism early.
  • Clinical diagnosis of PD is challenging, particularly at early stages when treatments are likely to be more effective.
  • For the first time in history, Amprion's breakthrough SYNTap Biomarker Test can help doctors effectively distinguish PD from Parkinsonism in early stages.
  • Our SYNTap Biomarker Test helps doctors diagnose Parkinson's, Lewy Body Dementia, and Alzheimer's with Lewy Bodies.

DGAP-News: AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Peripheral membrane proteins, PCSK9, Immunotherapy, Neurodegeneration, Synuclein, Alpha-synuclein, AFFiRiS AG, SAIT, neurodegenerative diseases, AFFIRIS AG, SAIT, NEURODEGENERATIVE DISEASES

"The acquisition of these programs by this pioneer in precision medicine and active vaccination for neurodegenerative diseases validates our AFFITOME(R) technology platform and the development projects based on it."

Key Points: 
  • "The acquisition of these programs by this pioneer in precision medicine and active vaccination for neurodegenerative diseases validates our AFFITOME(R) technology platform and the development projects based on it."
  • The Company's ultimate goal is to improve the lives of patients suffering from these diseases by providing specific immunotherapies.
  • Following the sale of its SAIT anti-alpha-synuclein programs to AC Immune in an all-stock transaction, AFFiRiS will concentrate on partnering activities to facilitate the further development of its programs in cardiovascular and neurodegenerative disease indications.
  • AFFiRiS published positive Phase 1 clinical results with active immunotherapies targeting PCSK9 to treat the cardiovascular condition hypercholesterolemia.

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Peripheral membrane proteins, Neuropathology, Synuclein, PCSK9, Alpha-synuclein, Immunotherapy, Vaccine, Neurodegeneration

Under the terms of the agreement, AC Immune is acquiring all of AFFiRiS assets and underlying intellectual property related to active vaccine candidates targeting alpha-synuclein and USD 5 million in cash for 7.1 million shares of AC Immune common stock based on a price of USD 8.26 per common share.

Key Points: 
  • Under the terms of the agreement, AC Immune is acquiring all of AFFiRiS assets and underlying intellectual property related to active vaccine candidates targeting alpha-synuclein and USD 5 million in cash for 7.1 million shares of AC Immune common stock based on a price of USD 8.26 per common share.
  • The acquisition of these programs by this pioneer in precision medicine and active vaccination for neurodegenerative diseases validates our AFFITOME technology platform and the development projects based on it.
  • Following the sale of its SAIT anti-alpha-synuclein programs to AC Immune in an all-stock transaction, AFFiRiS will concentrate on partnering activities to facilitate the further development of its programs in cardiovascular and neurodegenerative disease indications.
  • AFFiRiS published positive Phase 1 clinical results with active immunotherapies targeting PCSK9 to treat the cardiovascular condition hypercholesterolemia.